+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin cost-effectiveness in the United States for people at different vascular risk levels

Statin cost-effectiveness in the United States for people at different vascular risk levels

Circulation. Cardiovascular Quality and Outcomes 2(2): 65-72

Statins reduce the rates of heart attacks, strokes, and revascularization procedures (ie, major vascular events) in a wide range of circumstances. Randomized controlled trial data from 20,536 adults have been used to estimate the cost-effectiveness of prescribing statin therapy in the United States for people at different levels of vascular disease risk and to explore whether wider use of generic statins beyond the populations currently recommended for treatment in clinical guidelines is indicated. Randomized controlled trial data, an internally validated vascular disease model, and US costs of statin therapy and other medical care were used to project lifetime risks of vascular events and evaluate the cost-effectiveness of 40 mg simvastatin daily. For an average of 5 years, allocation to simvastatin reduced the estimated US costs of hospitalizations for vascular events by approximately 20% (95% CI, 15 to 24) in the different subcategories of participants studied. At a daily cost of $1 for 40 mg generic simvastatin, the estimated costs of preventing a vascular death within the 5-year study period ranged from a net saving of $1300 (95% CI, $15,600 saving to $13,200 cost) among participants with a 42% 5-year major vascular event risk to a net cost of $216,500 ($123,700 to $460,000 cost) among those with a 12% 5-year risk. The costs per life year gained with lifetime simvastatin treatment ranged from $2500 (-$40 to $3820) in people aged 40 to 49 years with a 42% 5-year major vascular event risk to $10,990 ($9430 to $14,700) in people aged 70 years and older with a 12% 5-year risk. Treatment with generic simvastatin appears to be cost-effective for a much wider population in the United States than that recommended by current guidelines.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911060

Download citation: RISBibTeXText

PMID: 20031817

DOI: 10.1161/CIRCOUTCOMES.108.808469

Related references

Statin cost effectiveness in primary prevention: a systematic review of the recent cost-effectiveness literature in the United States. Bmc Research Notes 5: 373-373, 2013

Cost-effectiveness analysis of brief and expanded evidence-based risk reduction interventions for HIV-infected people who inject drugs in the United States. Plos One 10(2): E0116694-E0116694, 2016

Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals. Lancet (North American Edition) 365(9473): 1779-1785,1769, 2005

Cost-Effectiveness of HIV Preexposure Prophylaxis for People Who Inject Drugs in the United States. Annals of Internal Medicine (): -, 2016

Assessment of statin therapy, LDL-C levels, and cardiovascular events among high-risk patients in the United States. Journal of Clinical Lipidology 10(1): 63-71.E1-3, 2016

Use of low density lipoprotein particle number levels as an aid in statin treatment decisions for intermediate risk patients: a cost-effectiveness analysis. Bmc Cardiovascular Disorders 16(1): 251-251, 2016

Cost-Effectiveness of Frequent HIV Testing of High-Risk Populations in the United States. Journal of Acquired Immune Deficiency Syndromes 71(3): 323-330, 2016

Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology 39(6): 313-320, 2016

A risk and cost effectiveness analysis of united states guidelines relative to radioactivity in foods. Health Physics 29(2): 307-312, 1975

Cost-effectiveness of total knee arthroplasty in the United States: patient risk and hospital volume. Archives of Internal Medicine 169(12): 1113-21; Discussion 1121-2, 2009

HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clinical Infectious Diseases 48(6): 806-815, 2009

Cost-effectiveness analysis of risk-factor guided and birth-cohort screening for chronic hepatitis C infection in the United States. Plos One 8(3): E58975-E58975, 2013

Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening. Journal of Lower Genital Tract Disease 19(4): 333-339, 2016